{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:51:03Z","timestamp":1791237063062,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.annder.2021.04.010","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T18:12:01Z","timestamp":1625767921000},"page":"262-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Omalizumab in chronic inducible urticaria: A retrospective, real-life study"],"prefix":"10.1016","volume":"148","author":[{"given":"M.","family":"Fialek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dezoteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Le Moing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Karimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ramdane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Azib-Meftah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Staumont-Sall\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2021.04.010_bib0140","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2021.04.010_bib0145","doi-asserted-by":"crossref","first-page":"864e5","DOI":"10.1016\/j.jaci.2017.01.043","article-title":"Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial","volume":"140","author":"Metz","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0150","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jaci.2019.02.005","article-title":"Treatments of cold urticaria: a systematic review","volume":"143","author":"Kulthanan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0155","doi-asserted-by":"crossref","first-page":"743e1","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2021.04.010_bib0160","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0165","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaci.2006.04.003","article-title":"Successful treatment of cold-induced urticaria\/anaphylaxis with anti-IgE","volume":"117","author":"Boyce","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0170","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jaad.2012.10.026","article-title":"Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases","volume":"69","author":"Le Moing","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2021.04.010_bib0175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000346284","article-title":"Treatment of severe cold contact urticaria with omalizumab: case reports","volume":"4","author":"Brodsk\u00e1","year":"2012","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.annder.2021.04.010_bib0180","first-page":"303","article-title":"Treatment of severe cold-induced urticaria in a child with omalizumab","volume":"25","author":"Alba Mar\u00edn","year":"2015","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000320233","article-title":"Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria","volume":"154","author":"Metz","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0190","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamadermatol.2013.8705","article-title":"Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria","volume":"150","author":"Metz","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2021.04.010_bib0195","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjd.14540","article-title":"Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients","volume":"175","author":"Ghazanfar","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2021.04.010_bib0200","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/pai.12609","article-title":"Omalizumab in pediatric cold contact urticaria: warm blanket for a cold bath?","volume":"27","author":"Kitsioulis","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.annder.2021.04.010_bib0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.anai.2013.12.005","article-title":"Real-life experiences with omalizumab for the treatment of chronic urticaria","volume":"112","author":"Sussman","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1398-9995.2009.02188.x","article-title":"Efficacy of omalizumab in delayed pressure urticaria: a case report","volume":"65","author":"Bindslev-Jensen","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2021.04.010_bib0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.anai.2015.10.009","article-title":"Successful treatment of occupational delayed pressure urticaria and angioedema with omalizumab","volume":"116","author":"Geller","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0225","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0394632015623795","article-title":"Effective treatment of different phenotypes of chronic urticaria with omalizumab: case reports and review of literature","volume":"29","author":"Kasperska-Zajac","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.annder.2021.04.010_bib0230","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2340\/00015555-2224","article-title":"Bullous delayed pressure urticaria responding to omalizumab","volume":"96","author":"M\u00fcller","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2021.04.010_bib0235","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaip.2016.07.016","article-title":"Rapid response to omalizumab in 3 cases of delayed pressure urticaria","volume":"5","author":"Quintero","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2021.04.010_bib0240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.aller.2012.11.001","article-title":"Successful treatment of severe delayed pressure angio-oedema with omalizumab","volume":"42","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2014","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.annder.2021.04.010_bib0245","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/pai.12407","article-title":"Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series","volume":"26","author":"Netchiporouk","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0250","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bjd.12628","article-title":"Effects of omalizumab in a patient with three types of chronic urticaria","volume":"170","author":"Vieira Dos Santos","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.annder.2021.04.010_bib0255","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaci.2018.08.050","article-title":"Real life treatment of cholinergic urticaria with omalizumab","volume":"143","author":"Altrichter","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2021.04.010_bib0260","doi-asserted-by":"crossref","first-page":"1599e1","DOI":"10.1016\/j.jaip.2018.12.025","article-title":"Efficacy and safety of omalizumab (Xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial","volume":"7","author":"Gastaminza","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2021.04.010_bib0265","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/bjd.19425","article-title":"Omalizumab for the treatment of chronic inducible urticaria in 80 patients","volume":"184","author":"Exposito-Serrano","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2021.04.010_bib0270","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaad.2015.11.021","article-title":"Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study","volume":"74","author":"Aubin","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963821000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963821000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:45Z","timestamp":1758971445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963821000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0151963821000636"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2021.04.010","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab in chronic inducible urticaria: A retrospective, real-life study","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2021.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}